A randomized clinical trial investigating local treatment for breast cancer liver metastases.
Breast cancer is the second most common cancer in Sweden. The purpose of this clinical trial is to evaluate local treatment for breast cancer liver metastases, compared to systemic oncological treatment only. The overall purpose is to ameliorate treatment for advanced breast cancer.
Head of project
Oskar HemmingssonAssociate professor, senior consultant (attending) physician, other position
Breast cancer is treated by a combination of surgery, radiotherapy, and medical treatment including chemotherapy, endocrine and targeted therapies. When distant metastasis beyond local lymph nodes occur, most patients receive oncological treatment and the role of surgery is uncertain. Some reports suggest there might be a survival benefit from resection of metastases in the liver while opponents to surgery argue that there is a lack of evidence and that an operation interrupts oncological treatment.
The purpose of this multicentre randomized clinical trial is to evaluate local treatment for breast cancer liver metastases, compared to systemic oncological treatment only. The primary endpoint is time to death from any cause. The secondary endpoints are three years survival, progression-free survival, median overall survival, breast cancer specific survival and quality of life. The aim is also to evaluate overall safety and predictive factors for survival during oncological and surgical treatment. The overall purpose is to ameliorate treatment for advanced breast cancer.
PhotoIve Van Krunkelsven
Norrlands University Hospital Umeå Sahlgrenska University Hospital Gothenburg Skane University Hospital Lund Akademiska University hospital Uppsala University Hospital of Linkoping Karolinska University Hospital Huddinge